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The newDSM-5 “withmixed features” specifier (MFS) has renewed the interest of the scientific community inmixed states, leading
not only to new clinical studies but also to new criticisms of the current nosology. Consequently, in our paper we have reviewed
the latest literature, trying to understand the reactions of psychiatrists to the new nosology and its epidemiological, prognostic,
and clinical consequences. It seems that the most widespread major criticism is the exclusion from the DSM-5 MFS of overlapping
symptoms (such as psychomotor agitation, irritability, and distractibility), with a consequent reduction in diagnostic power. On
the other hand, undoubtedly the new DSM-5 classification has helped to identify more patients suffering from a mixed state
by broadening the narrow DSM-IV-TR criteria. As for the clinical presentation, the epidemiological data, and the therapeutic
outcomes, the latest literature does not point out a univocal point of view and further research is needed to fully assess the
implications of the new DSM-5 MFS. It is our view that a diagnostic category should be preferred to a specifier and mixed states
should be better considered as a spectrum of states, according to what was stated many years ago by Kraepelin.
1. Introduction
Thecurrent notion ofmood disorders is based on the contrast
between two most important concepts: on the one hand,
Kraepelin [1], together with his famous successor Weygandt,
considered all recurrent mood states, whether depressive
or manic, as one illness, manic-depressive insanity, and
thought that mixed states were the most common version of
manic-depressive illness [2]. On the other hand, Leonhard
distinguished patientswith unipolar disorder from thosewith
bipolar disorder on the basis of genetic and course findings,
leading to the bipolar/unipolar dichotomy [3].
The DSM nosology of mood is neo-Leonhardian and
not Kraepelinian [4]. Consequently, mixed states, as an
overlapping of manic and depressive symptoms, have been
almost completely neglected for decades, mainly under the
influence of Kurt Schneider who promoted the idea that what
may give the impression of the combination of manic and
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depressive features actually should not be considered a mood
disorder [5].
A renewed interest in mixed states has developed after
the new DSM-5 “with mixed features” specifier (MFS), even
though the latest literature does not point out a univocal
point of view [6] on the validity and utility of this new
classification formixed states. Some authors [7] suggest that it
would capture subthreshold nonoverlapping symptoms of the
opposite pole; others consider it to lead tomoremisdiagnosis
and inadequate treatment [4]. Consequently, there is pressing
need to validate the DSM-5 MFS in further research [8].
But what is the state of the art of the DSM-5 MFS? In
order to give an answer to this question, we reviewed the
latest literature on mixed states, in consideration of the new
MFS in DSM-5, trying to understand the reactions of the
psychiatric scientific community to the new nosology and its
epidemiological, prognostic, and clinical consequences.
2. Materials and Methods
An electronic search using the MEDLINE database of pub-
lished peer-reviewed papers was conducted in order to find
the most up-to-date studies about mixed states according to
the newDSMnosology, considering those published between
January 2011 and February 2015. We used two groups of key
words linked with the word AND: (1) bipolar mixed features,
depressive mixed features, mixed features, mixed states; (2)
DSM-5. We excluded studies published in other languages
than English, “grey literature,” letters to the editor, studies
about a paediatric population, and those using DSM-IV-TR
criteria for mixed states.
3. Results
In our electronic search we found 37 papers and included
in our review 19 papers according to our exclusion criteria.
We decided to divide the papers into two main categories: (1)
reviews and opinions about mixed states in DSM-5 (𝑛 = 9);
(2) research reports (𝑛 = 11), with three subcategories: (2.1)
clinical research reports (𝑛 = 5); (2.2) research reports about
pharmacological treatment in the presence of MFS (𝑛 = 3);
(2.3) research reports about diagnostic tools for mixed states
(𝑛 = 2). The papers considered in the review are listed as
follows, divided according to the specific categories.
Summary of the Papers Considered in the Review, Divided
according to Specific Categories
(1) Reviews and opinions about mixed states in DSM-5:
Koukopoulos et al., 2013 [4],
Koukopoulos and Sani, 2014 [9],
Uher et al., 2014 [10],
Perugi et al., 2014 [5],
Vieta and Valent´ı, 2013 [7],
de Dios et al., 2014 [11],
Liu and Jiang, 2014 [12],
Castle, 2014 [13],
First, 2011 [14].
(2) Research reports:
(2.1) clinical research reports:
McIntyre et al., 2015 [15],
Malhi et al., 2014 [16],
Vieta et al., 2014 [17],
Perlis et al., 2014 [18],
Takeshima and Oka, 2015 [19],
(2.2) research reports about pharmacological treat-
ment in the presence of MFS:
McIntyre et al., 2013 [8],
Tohen et al., 2014 [20],
Tohen et al., 2014 [21],
(2.3) research reports about diagnostic tools for
mixed states:
Hergueta and Weiller, 2013 [22],
Zimmerman et al., 2014 [23].
3.1. Reviews and Opinions about Mixed States in DSM-5.
According to Koukopoulos and colleagues [4], the newDSM-
5 MFS can lead to more problems in diagnosis, mainly in
mixed depression. In fact, the DSM-5 task force decided to
exclude from theMFS those manic and depressive symptoms
that can overlap, leading to the exclusion of psychomotor
agitation, irritability, and distractibility.
In an empirical study [9] the same authors found out that
the frequency of mixed-mood states similar to the DSM-5
definition ranged from 0 to 12%. On the contrary, using a
definition including those overlapping symptoms as central
features of mixed depression, the frequency ranged from 33
to 47% [4].
It is for this reason that the authors [4] proposed the
traditional name of “agitated depression” for depressive
syndromes with psychomotor agitation and that the name
“mixed depression” can be used in the absence of psychomo-
tor agitation.
Furthermore,Uher and colleagues [10], when considering
the implications for clinical practice and research of the
changes between DSM-IV-TR and DSM-5, pointed out that
the symptomof psychomotor agitation has been deleted from
the MFS but added in the “with anxious distress” DSM-5
specifier in the fourth grade (“severe”), with the possibility
of more misdiagnosis. In addition, they pointed out that
irritability, which is seen in up to 40% of outpatients with
major depressive disorder (MDD), contributes to episode
severity and predicts recurrence but is not included among
criteria for MDD in adults, not even in the MFS.
In addition, Perugi and colleagues [5] reported that even
though the DSM-5 definition is based on the speculative wish
to avoid “overlapping” manic and depressive symptoms, this
combinatory model seems more appropriate for less severe
forms, in which mood symptoms are clearly identifiable.
Another major criticism that Koukopoulos and col-
leagues [9] have made to the new DSM-5MFS was that those
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hypo/manic symptoms required in a depressive episode to
consider theMFS (i.e., elevated/expansivemood or grandios-
ity) are the least common symptoms that actually arise in
depressive mixed states.
In 2013 Vieta and Valent`ı [7] published an enthusiastic
review aboutmixed states inDSM-5.They stated that the new
classification would capture subthreshold nonoverlapping
symptoms of the opposite pole and would have a substantial
impact in several fields, mainly because it would overcome
the extremely narrowdefinition inDSM-IV-TR. In fact, fewer
symptoms (than in DSM-IV-TR) of the opposite polarity are
included in the MFS and the definition can be applied in
more groups of disorders, not only in bipolar disorder I-
BDI but also in bipolar disorder II-BDII, bipolar disorder
not otherwise specified (BD-NOS), and, in particular, MDD,
which is a link to the mood spectrum concept of Akiskal
[24]. However, in the conclusions, the authors stated that the
specificity and sensitivity of this diagnostic construct would
need to be assessed by new and additional empirical studies.
In fact, the same group [11] published in the following
year a review about bipolar disorders in DSM-5 focused on
the fact that the decision to exclude common symptoms such
as irritability, distractibility, or psychomotor agitation in spite
of recognising the need to change the previous DSM-IV-TR
strict criteria has been criticised as not very scientific and as
lacking validity. Furthermore, they pointed out that themixed
nature of affective episodes became a course specifier with
the disappearance of the category of mixed episode in bipolar
disorders. In addition, the authors reported that agreement
in diagnosis based on separate interviews by physicians who
received training in the use of DSM-5 is moderate for bipolar
disorder type (kappa: 0.56) and somewhat less for type II
(kappa: 0.40) [11] and is the lowest ever reported for theMDD
diagnosis (kappa: 0.28) [10].
Liu and Jiang [12] believed that one of the reasons for
this could be the blurring of the depressive/bipolar disorder
boundary.
Castle [13] stated that a major problem with the mixed
states literature is the lack of uniform ways of measuring
these syndromes and reported two examples of scales, one
by Cavanagh et al. [25] comprising 18 items divided into
an A group of manic items and a B group of depressive
items. The author considered this scale of clinical utility
because it is brief but requires validation in a depressed
sample. The Multidimensional Assessment of Thymic States
(MAThyS) was instead proposed by Henry et al. [26] and
rated two dimensions, namely, activation/inhibition and
emotional reactivity. The former was seen to be associated
only with depression and the latter with manic and mixed
symptoms.
Finally, according to the cost-benefit analysis drawn up by
First [14], the new DSM-5 MFS is at odds with the previous
empirical data and its overall treatment implications are also
unclear. It was suggested that, by raising clinicians’ awareness
of the presence of mixed features through the introduction of
this specifier, pressure will be exerted to do something with
this information but without empirical evidence as a guide,
it was not clear whether the possible interventions would do
more good than harm.
3.2. Research Reports
3.2.1. Clinical Research Reports. In 2015, McIntyre and col-
leagues [15] published the results of The International Mood
Disorders Collaborative Project (IMDCP). A total of 982
individuals who met criteria for a current mood episode as
part of MDD (𝑛 = 506) or BD (𝑛 = 346; BDI: 𝑛 = 216, BDII:
𝑛 = 130) were included in the analysis and the DSM-5 MFS
was evaluated using proxies by means of the Young Mania
Rating Scale (YMRS) or the Montgomery Asberg Depression
Rating Scale (MADRS) or the Hamilton Depression Rating
Scale-17 items (HAMD-17). The authors found that 26.0%
(𝑛 = 149) of patients diagnosed with a MDD, 34.0% (𝑛 = 65)
of BDI patients, and 33.8% (𝑛 = 49) of individuals with BDII
met the criteria for MFS during a mood depressive episode
(MDE). On the contrary, MFS during a hypo/manic episode
was identified in 20.4% (𝑛 = 52) of BDI participants and in
5.1% (𝑛 = 8) of individuals suffering from BDII.
Malhi and colleagues [16] conducted a study in order to
examine the relative distribution of psychomotor agitation
and distractibility in 200 patients divided into four groups:
BD, BDspectrum, and unipolar depression (UP) and mixed
depression (UPmix). The study was based on a self-report
structured diagnostic assessment and a clinical psychiatric
evaluation. The authors found that increased distraction,
racing thoughts, and increased irritability were the most
commonly reported manic symptoms amongst the UP group
(𝑛 = 24, 17.6%). Furthermore, UPmix and BDspectrum
groups had significantly higher psychomotor agitation (F (3,
122) = 8.04, 𝑃 < 0.001) than the other two groups and
distractibility was more represented in the UPmix (71%) and
BDspectrum (67%) than in the UP (54%) and BD (40%)
groups.
As for hypo/manic episodes with mixed features, in
2013 Vieta and colleagues [17] published the results of a
multicenter, international online survey (the IMPACT study)
conducted in order to describe the phenomenology of mania
and depression in bipolar patients experiencing a manic
episode with mixed features. Seven hundred patients with
a manic episode with or without DSM-5 criteria for mixed
features from 7 countries completed a 54-item questionnaire
on demographics, diagnosis, symptomatology, communica-
tion of the disease, impact on life, and treatment received.
Data was collected between March 26 and July 31, 2012. The
authors found that 39% (𝑛 = 275) of patients reported ≥3
DSM-5 depressive symptoms during a past manic episode.
These patients were more likely to have had a delay in
diagnosis, were more likely to have experienced shorter
symptom-free periods, and were characterized by a marked
lower prevalence of typical manic manifestations. Indeed,
only physical aggression and abusive behaviour towards
others were more frequently reported by individuals in the
mania with depressive symptoms group (𝑃 = 0.001 and
𝑃 = 0.02). Furthermore, the authors also recorded a
high rate of misdiagnosis (39% in the case of mania with
depressive symptoms group); in particular these patients
were significantly more frequently misdiagnosed as having
insomnia than those without depressive symptoms (46.7%
versus 27.9%; 𝑃 < 0.0001).
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As for MDE with mixed features, Perlis and colleagues
[18] examined outcomes between patients with MDD partic-
ipating in the Sequenced Treatment Alternatives to Relieve
Depression (STAR∗D), hypothesizing that mixed symptoms
in MDD would be associated with poorer antidepressant
treatment outcomes. 9.6% (𝑛 = 231) of patients reported
three or more mixed symptoms. The presence of such symp-
toms, in particular expansive mood and cheerfulness, was
associated with a greater likelihood of remission (adjusted
hazard ratio 1.16, 95% confidence interval 1.03–1.28). The
authors concluded that this challenges the view that mixed
features may be associated with poorer outcomes in MDD
and questioned the notion that these features are or are not
to be considered to be in the “bipolar spectrum.”
Takeshima and Oka [19] reported the data of 217 patients
with MDE (BDII: 𝑛 = 57, BD-NOS: 𝑛 = 35, MDD:
𝑛 = 125) firstly diagnosed according to DSM-IV-TR; at
a later stage, the authors analyzed the prevalence of mixed
depression according to both the DSM-5 MFS and Benazzi’s
definition (which includes all manic/hypomanic symptoms
in MDE). The aim of the study was to assess if the lack of
the three symptoms, irritability, psychomotor agitation, and
distractibility, in theDSM-5MFS could cause underdiagnosis
of mixed depression. The authors identified more patients
with Benazzi’s mixed depression and DSM-5 defined mixed
features in BD than inMDD (46.7% versus 12.8%,𝑃 < 0.0001,
resp., according to Benazzi; 4.3% versus 0%, 𝑃 = 0.0208,
resp., according to DSM-5). Furthermore, they stated that the
sensitivity/specificity for BD diagnosis according to Benazzi’s
mixed depression and DSM-5 defined mixed features were
55.1%/87.2% and 5.1%/100%, respectively.
3.2.2. Research Reports about Pharmacological Treatment in
the Presence of MFS. McIntyre and colleagues [8] described
the frequency of depressive mixed features in BDI patients
with manic episode by using MADRS and PANSS items
as proxies for the DSM-5 MFS. They found that 34.2%
(𝑛 = 328), 17.5% (𝑛 = 168), and 4.3% (𝑛 = 41) of the
patients had at least 3 MADRS items with mild, moderate,
and severe symptoms, respectively. Furthermore, the authors
randomized the patients to asenapine, placebo, or olanza-
pine, showing that the symptomatic improvement of the
manic/hypomanic symptoms was significant and superior to
placebo for both asenapine and olanzapine, but for the former
this was true regardless of depressive symptom severity, while
on the contrary, for the latter the statement was true only in
individuals with lower baseline depressive symptom severity.
Tohen and colleagues [20] investigated the correlations
between the efficacy of olanzapine monotherapy (evaluated
by change in MADRS total score from baseline to 6 weeks)
and the number of concurrentmanic symptoms (asmeasured
by a Young Mania Rating Scale item score ≥1) in patients
treated for bipolar depression. The percentage of patients
in mixed feature ≥3 categories was 30.5% by using the
11 YMRS items and 11.9% by using the 6 YMRS items.
Due to the fact that the least-square mean differences in
MADRS total score and the effect sizes were similar when
the authors considered 0, 1, or 2 and ≥3 mixed symptoms,
they concluded that olanzapine worked similarly on bipolar
depression irrespective of the number of concurrent manic
symptoms.
The same authors published in a following paper [21] data
about the comparison of the efficacy of olanzapine (evaluated
by changes in the baseline-to-3-week YMRS total score) in
patients with bipolar mania with or without DSM-5 mixed
features (as determined by HAMD-17-item score ≥1). Sixty-
six patients in the placebo group and 59 in the olanzapine
group showed ≥3 mixed symptoms, in total 28% of the
sample. Contrary to what happened for bipolar depression
[20], olanzapine was efficacious in the treatment of bipolar I
mania, in both patients without and with mixed features, but
greater efficacy was seen in patients with mixed features who
had more severe depressive symptoms (with mixed features
effect size = 0.34; without mixed features effect size = 0.20).
3.2.3. Research Reports about Diagnostic Tools for Mixed
States. Hergueta and Weiller [22] reported the results of a
validation study about a new module of the Mini Inter-
national Neuropsychiatric Interview (M.I.N.I.) developed
as a patient-completed questionnaire in order to evaluate
the DSM-5 MFS for hypo/manic episodes. The study was
conducted in two phases; the first one involved verifica-
tion of bipolar patients’ acceptance and comprehension of
the questions in the module; the second consisted in the
assessment of the degree of agreement between patients’
responses using the M.I.N.I. module versus DSM-5 criteria
as evaluated by psychiatrists. First of all, the authors reported
that according to psychiatrists 46.5% (46/99) of patients
met the DSM-5 MFS criteria but patients were more likely
than psychiatrists to report the presence of at least three
depressive symptoms (58.6%, 58/99). As for the agreement, it
was substantial (Cohen’s kappa coefficient = 0.60), the overall
sensitivity of the M.I.N.I. was 0.91; and its specificity was
0.70. The module’s positive and negative predictive values
were 0.72 and 0.90. Interestingly enough, the highest levels of
agreement were for the most common symptom (depressed
mood, 79%) and themost severe symptom (suicidal thoughts,
85%), and the lowest level of agreement was for the least
severe symptoms (i.e., fatigue, 64% to 65%). As a conse-
quence, the authors considered this tool useful in clinical
and epidemiological research and suggested that it should be
incorporated into routine psychiatric evaluation of patients
withmanic episodes and that a correspondingmodule should
be developed for evaluating “hypomanic features” during
bipolar or unipolar major depressive episodes.
In fact, in 2014 Zimmerman and colleagues [23] mod-
ified their previously published depression scale (Clinically
Useful Depression Outcome Scale (CUDOS)) to include a
subscale assessing the DSM-5 MFS (CUDOS-M) in order
to acknowledge the clinical significance of manic features in
depressed patients. The CUDOS-M demonstrated excellent
internal consistency (Cronbach’s 𝛼 = 0.84), the test-retest
reliability of the total scale was high (𝑟 = 0.72), and the test-
retest reliability of each item was significant (mean 𝑟 = 0.56)
though 3 items had a test-retest reliability of less than 0.30;
consequently, the authors stated that repeated administration
of such ameasure during the course of treatment could enable
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clinicians to identify patients whose depressive episodes are
evolving into a mixed state more readily and quickly.
4. Discussion
In our review, the percentage of hypo/manic episodes with
mixed features ranges from 4.3% [8] to 58.6% [22]. The
percentage of MDE with mixed features is lower and ranges
from 0 [9, 19] to 34% [15]. These extremely broad ranges can
be due to the quite low sensitivity of the DSM-5 MFS (5.1%)
[19].
In fact, some authors suggested that DSM-5 has lowered
the threshold for mixed states by limiting the symptoms that
confer mixed features (psychomotor agitation, irritability,
and distractibility), losing the essence of the clinical presen-
tation [16].
Malhi et al. [16] stated that the exclusion of these sym-
ptoms would alter the trajectory of research and the implica-
tions of future findings.
According to this, in the research report published
by Vieta and colleagues [17] more patients in the mania
with depressive symptoms group had symptoms of anxiety
and irritability associated with agitation than those without
depressive symptoms (72.4% versus 27.1%; 𝑃 < 0.0001).
Furthermore, in Takeshima and Oka’s study [19] psychomo-
tor agitation was the manic/hypomanic symptom that was
observed most frequently in both patients with BD (59.8%)
and those with MDD (48.8%).
In the M.I.N.I. module for the DSM-5 MFS validation
[22] psychomotor retardation was found to be the depressive
symptom that patients presented least frequently during a
hypo/manic episode.
The previous findings are in line with previous re-
searchers’ belief [27] that psychomotor agitation and dis-
tractibility are symptoms of particular interest because both
have been identified as putative drivers inmixed episodes and
are associated with poorer treatment outcomes [16, 28].
However, undoubtedly the new DSM-5 classification has
helped to identify more patients suffering from a mixed
state than the previous nosology and this may have clinical
consequences. In fact, in McIntyre and colleagues [15] study,
hypo/mania with MFS was identified in 20.4% (𝑛 = 52) of
BDI participants of which 12.9% (𝑛 = 33) met criteria for a
DSM-IV-TRdefinedmixed episode; thismeans that 7.5% (𝑛 =
19) of patients in this sample were considered not to have a
mixed episode according to the previous nosology. In another
study conducted by the same authors [8] between 20 and 40%
(depending on symptom severity) of patientsmeeting criteria
for DSM-5 defined mixed specifier did not meet DSM-IV-
TR defined mixed features. Only Takeshima and Oka [19]
found that the prevalence of DSM-5 MFS (4.3%) in the BD
sample was lower than that of cooccurrence of MDE and
HME (comparable with DSM-IV-TR defined mixed episode,
15.2%).
Consequently, another consideration is that it could
be important to assess, in further studies, the interrater
reliability between psychiatrists for the DSM-5 MFS, looking
at their low rates of agreement in diagnosis of bipolar and
depressive disorders in DSM-5.
As for the prognostic implications, the results are still
inconclusive. McIntyre and colleagues [15] underlined the
fact that individuals withMDD-MFS exhibited a significantly
more severe depression than did individuals with MDD
without MFS (adjusted 𝑃 = 0.0002 and 𝑃 < 0.0002, resp.) or
BD-MDEwithoutMFS (adjusted𝑃 = 0.0001 and𝑃 < 0.0001,
resp.).
Finally, individuals with MFS exhibited a higher rate of
alcohol/substance use disorder in the context of BD [15] and
a younger age at onset [20, 21], as stated in previous researches
based on DSM-IV-TR [29–31] meaning that some clinical
presentations and disorders in comorbidity are intrinsic to
the psychopathology of mixed states and do not depend on
the classification used in making a diagnosis.
5. Conclusions
The effects and clinical implications associated with the use
of the DSM-5 MFS have yet to be fully assessed. Most of the
research reports considered in our review were retrospective
or used proxies for MFS. Systematic, prospective assessment
of mixed symptoms in large population-based cohorts of
individuals withMDD or BDwas required to understand the
meaning and the utility of these symptoms inmood disorders
[18]. Furthermore, it is important to ascertain which of the
associated features, such as anxiety and substance abuse, are
symptomatic of the mixed state itself and which might be
amenable to avert poor prognostic outcomes [13].
The identification of additional patients with mixed
features according to the updated DSM-5 compared to the
DSM-IV-TR definition affirms that the separation of these
subtypes of mood episodes from manic or depressive states
is necessary in clinical settings mainly to enable the selection
of the most effective treatments [8].
Even though the DSM-5 approach considers mixed states
as subtypes of manic or depressive episodes [5], mixed
depression and mixed mania deserve their own diagnostic
identity [4]. In fact, a diagnostic category should be preferred
to a specifier, because it will increase focus on mixed states
[11], which should be better considered as a spectrumof states
backed by the gradation from typical depressive symptoms to
typical manic symptoms [19], bringing the current notion of
mixed states back to what has been argued by Kraepelin [1]
and Akiskal [24].
On the basis of the papers considered in this review, the
authors state that the current data are not conclusive; in fact,
it is not clear how this new classification can impact the
bipolar-unipolar dichotomy and diagnostic reliability, mainly
because of the new possibility to diagnose major depression
with mixed features [7]. Consequently, further research is
needed in order to better understand the implications of the
new nosology for epidemiology, clinical care, prognosis, and
psychopharmacological treatment of bipolar and unipolar
depressed patients that show mixed states features.
It would be important to assess if manic/hypomanic or
depressive episodes with mixed features would represent
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homogeneous groups; maybe, the homogeneity of the differ-
ent groups can be just explained by the exclusion from the
MFS of those manic and depressive symptoms that overlap,
such as psychomotor agitation, irritability, and distractibility.
Besides, this is the major criticism to the new classification,
so its validity needs to be assessed in clinical studies.
In addition, it could be useful to identify the neuro-
biological, neurocognitive, or neuroimaging correlates that
differentiate the different episodes with or without mixed
features.
For example, the possibility to separate MDD with and
without MFS might help in both identifying patients with
worse prognosis and prescribing a more appropriate therapy
[7].
It is known that higher rates of suicidal ideation as
well as higher frequencies of antidepressant use can be
found in bipolar patients with mixed features [32]. As a
consequence, studies need to be done in order to assess
the increased suicidality in manic/hypomanic and depressed
patients with MFS compared to those without MFS, both in
bipolar patients and inMDDpatients. In fact, this could allow
for supporting the recommendation to avoid antidepressant
treatment in these patients unless strictly in tandem with
mood stabilisers [33] or antipsychotic medications [34].
Furthermore, mood stabilizers and atypical antipsy-
chotics are recommended to treat mixed episodes [34] but
data is limited to subanalyses or post hoc analyses of popu-
lations of patients with both manic and mixed episodes [7].
Consequently, it would be helpful to involve in randomized
prospective trials homogeneous cohorts of mixed patients
[34], divided according to the new DSM-5 classification, in
order to assess remission rates and prophylactic benefits of
the most important mood stabilizers and antipsychotics.This
could be innovative mainly in consideration of the fact that
patients suffering from MDD with or without MFS can be
separated and this can help to distinguish patients that could
respond to adjunctive antipsychotics or mood stabilizers
from those who would not [7].
At the epidemiological level, the lifetime prevalence of
both bipolar disorders and MDD would change and this
could be due to the fact that the new MFS could decrease
the prevalence of bipolar disorder not otherwise specified
(BD-NOS), increasing the prevalence of the specific episodes;
this data should be compared to those existing data on
mixed states, based on the previous classifications, in order to
evaluate the possible differences on epidemiology, morbidity,
response to treatment, illness course, and outcomes. In
addition, the comparison with this previous data could be
useful to ascertain the validity and clinical utility of the new
DSM-5 classification [7].
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